v3.19.3.a.u2
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Operating costs and expenses:            
Research and development $ 1,036,689 $ 3,459,681 $ 6,044,580 $ 6,180,607 $ 11,366,117 $ 2,874,184
Patent costs 20,867 59,068 139,436 170,418 204,396 250,372
General and administrative 1,122,825 1,144,750 3,621,888 3,957,545 5,425,033 4,777,902
Total operating costs and expenses 2,180,381 4,663,499 9,805,904 10,308,570 16,995,546 7,902,458
Operating loss (2,180,381) (4,663,499) (9,805,904) (10,308,570) (16,995,546) (7,902,458)
Other income (expense):            
Interest income 13,172 17,237 117,777 64,965 126,835 40,227
Other expense         (1,627)
Total other income 13,172 17,237 117,777 64,965 126,835 38,600
Net loss (2,167,209) (4,646,262) (9,688,127) (10,243,605) (16,868,711) (7,863,858)
Other comprehensive income:            
Unrealized gain (loss) on debt securities 923 (923)
Comprehensive loss (2,167,209) (4,646,262) (9,687,204) (10,243,605) (16,869,634) (7,863,858)
Net loss $ (2,167,209) $ (4,646,262) $ (9,688,127) $ (10,243,605) (16,868,711) (7,863,858)
Deemed dividend of preferred stock         (2,537,844) (3,111,020)
Net loss applicable to common stockholders         $ (19,406,555) $ (10,974,878)
Net loss per common share - basic and diluted $ (0.23) $ (0.86) $ (1.09) $ (2.00) $ (3.66) $ (4.95)
Weighted average common shares outstanding - basic and diluted 9,507,636 5,373,769 8,873,947 5,129,351 5,304,667 2,214,951